AcceGen Biotechnology
Private Company
Total funding raised: $1.2M
Overview
AcceGen Biotechnology operates as a specialized research products and services company, catering primarily to academic, pharmaceutical, and biotechnology research labs. Its core business involves the sale of high-quality, well-characterized cell products and the provision of custom cell line development and gene editing services. While not a therapeutic developer itself, AcceGen supports the broader biotech ecosystem by providing essential tools for drug discovery, target validation, and preclinical research. The company appears to be a private, revenue-generating entity serving a global customer base from its base in Fairfield, New Jersey.
Technology Platform
Biobanking of primary and immortalized cell lines; Custom cell line engineering (stable transfection, knockout/knockin); iPSC gene editing; Cell immortalization services; Lentivirus packaging; MicroRNA reagent synthesis.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
AcceGen competes in the fragmented life science research products market against giants like ATCC and Thermo Fisher Scientific, as well as numerous specialized cell line providers (e.g., ZenBio, PromoCell). Its differentiation hinges on a broad catalog, custom service capabilities, and a focus on specific cell types, but it lacks the scale and brand recognition of the market leaders.